Your browser does not support JavaScript!

Santé humaine biotechnologies domaine d'application

505 entreprises et organismes intervenants dans le domaine 'Santé humaine', classés par activité.

Rejoignez la communauté
CELLECTIS
est cité dans une actualité de FierceBiotech
Il y a 4 jours

Chutes & Ladders—Off-the-shelf CAR-T player Cellectis poaches Novartis executive

Il y a 6 jours
Off-the-shelf CAR-T player Cellectis poached Novartis oncology executive Stefan Scherer, M.D., Ph.D.; GlaxoSmithKline recruited a new CFO to spearhead cost-cutting; and Thomas Hughes left Zafgen to...
www.fiercebiotech.com
PFIZER
est cité dans une actualité de FierceBiotech
Il y a 1 semaine

Pfizer contracts with Antares to build a rescue auto-injector for an unnamed drug

Il y a 1 semaine
Pfizer has tapped Antares Pharma for the development of a self-administered combination drug-device rescue pen for an undisclosed medicine, shortly after investing $465 million in a new sterile...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 1 semaine

Merck, HitGen expand DNA library screening collaboration

Il y a 1 semaine
Merck and HitGen have upsized their licensing agreement into a full-fledged, multiyear drug discovery collaboration, with plans to screen DNA-encoded libraries for new small molecule assets....
www.fiercebiotech.com
CELLECTIS
est cité dans une actualité de FierceBiotech
Il y a 1 semaine

CAR-T player Cellectis poaches Stefan Scherer from Novartis

Il y a 1 semaine
Cellectis has named Stefan Scherer, M.D., Ph.D., as its SVP of clinical development. Scherer joins the off-the-shelf CAR-T pioneer from Novartis, where he headed up U.S. oncology early development and...
www.fiercebiotech.com
LILLY FRANCE
est cité dans une actualité de FierceBiotech
Il y a 1 semaine

Karuna raises $42M to resurrect abandoned Lilly drug for schizophrenia

Il y a 1 semaine
Karuna Pharmaceuticals has the cash it needs to start mid-stage trials of an Eli Lilly drug, shelved because of side effects, as part of a combination therapy for schizophrenia and Alzheimer’s....
www.fiercebiotech.com
SANOFI AVENTIS
est cité dans une actualité de FierceBiotech
Il y a 1 semaine

Sanofi diabetes executive makes the jump to Omeros to become CMO

Il y a 1 semaine
In keeping with the recent trend of top R&D executives moving to smaller biotechs, Sanofi’s Eckhard Leifke, M.D., the giant’s global head of diabetes late-stage development, is making the jump to...
www.fiercebiotech.com
PFIZER
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

Pfizer drops diabetes and cancer drugs from clinical pipeline

Il y a 2 semaines
Pfizer has culled Type 1 diabetes and cancer drugs from its early-phase pipeline. The actions affect anti-IL7R antibody PF-06342674 and third-generation, mutant-selective EGFR tyrosine kinase...
www.fiercebiotech.com
PFIZER
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

Beijing’s CANbridge brings on Pfizer rare disease leader as CMO to help bring new drugs to China

Il y a 2 semaines
Beijing’s CANbridge Life Sciences, which develops Western drug candidates in China and Asia, brought on Pfizer’s May Orfali to be its new chief medical officer....
www.fiercebiotech.com
LILLY FRANCE
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

Lilly firms up cancer collaboration with Dana-Farber

Il y a 2 semaines
Eli Lilly must be seeing value in its broad-ranging research collaboration with the Dana-Farber Cancer Institute, as it’s extending the partnership for another three years....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

MilliporeSigma, InnoCore team up on extended-release platform for large biologics

Il y a 2 semaines
Merck KGaA’s U.S. life science arm, MilliporeSigma, will collaborate with InnoCore Pharmaceuticals to offer a drug delivery platform for sustained-release formulations for “virtually any class” of...
www.fiercebiotech.com
Charger plus d'actualités